Upload
christan-chaputtra-maharibe
View
216
Download
0
Embed Size (px)
Citation preview
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 1/57
Thalassemia &Hemoglobinopathies
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 2/57
What is thalassemia?
Genetic blood disorder resulting in a mutation ordeletion of the genes that control globin production.
Normal hemoglobin is composed of 2 alpha and 2
beta globins Mutations in a given globin gene can cause a
decrease in production of that globin, resulting indeficiency
aggregates become oxidized damage the cellmembrane, leading either to hemolysis, ineffectiveerythropoiesis, or both.
2 types of thalassemia: alpha and beta.
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 3/57
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 4/57
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 5/57
Alpha Thalassemia
mutation of % or more of the & alpha globin
genes on chromosome %'
severity of disease depends on number ofgenes affected
results in an excess of beta globins
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 6/57
Silent Carriers (heterozygotes +/-
( functional alpha globin genes
No symptoms, but thalassemia could
potentially appear in offspring
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 7/57
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 8/57
Hemoglobin H Disease
% functional globin gene
results in very lightly coloured red blood cells
and possible severe anemia hemoglobin ) is susceptible to oxidation,
therefore oxidant drugs and foods are
avoided
treated ith folate to aid blood cell production
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 9/57
Alpha Thalassemia !a"or
no functional globin genes
death before birth *embryonic lethality+
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 10/57
#eta Thalassemia
mutations on chromosome %%
hundreds of mutations possible in the beta
globin gene, therefore beta thalassemia ismore diverse
results in excess of alpha globins
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 11/57
#eta Thalassemia Trait
slight lac of beta globin
smaller red blood cells that are lighter in
colour due to lac of hemoglobin no ma-or symptoms except slight anemia
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 12/57
#eta Thalassemia $nterme%ia
lac of beta globin is more significant
bony deformities due to bone marro trying to mae
more blood cells to replace defective ones
causes late development, exercise intolerance, andhigh levels of iron in blood due to reabsorption in the
G$ tract
if unable to maintain hemoglobin levels beteen '
gmdl / 0 gmdl, transfusion or splenectomy is
recommended
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 13/57
#eta Thalassemia !a"or
complete absence of beta globin
enlarged spleen, lightly coloured blood cells
severe anemia chronic transfusions re1uired, in con-unction
ith chelation therapy to reduce iron
*desferoxamine+
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 14/57
!ore ermanent 'ptions
one Marro Transplants 3eplacing patient4s marro ith donor marro 5irst performed on thalassemia patient in %67% 8ifficult, because donor must be exact match for
recipient 9ven a sibling ould only have a % in & chance of
being a donor
#ord lood Transplants 3ich in stem cells "lso needs to be an exact match
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 15/57
Strctre hemoglobin
Globin portion olypeptide chain
Normal adult hemoglobin*)b"+ is composed %&%
amino acid residues of α chain and %&' amino acid ofβ chain
)eme portion
$ron and porphyrin
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 16/57
Clasi)ication
Thalasemia trait Normal performance
$ntermediate )b range around %; / %% gdl
Mayor thalasemia )b < 7 gdl
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 17/57
Hematologic changes
)b range from 2 / 7 gdl The red cells )ypochromia
=ariation in size and shape 5ragmentosis asophilic stippling Nucleated red cells in peripheral blood, especially
after splenectomy 3eticulocyte count is elevated
)b5 level is eleveated
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 18/57
-Thalasemia
β;>Thalasemia : no detactable β>chain synthesis
absent β chain m3N"
β?>Thalasemia : reduced β>chain synthesis
reduced or nonfunctional β chain m3N"
)ereditary persistence of fetal hemoglobin
δβ>Thalasemia : δ and β>chain genes deleted
)b @epore : δ and β>chain genes partiallydeleted
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 19/57
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 20/57
Heterozygos states o) -Thalasemia
Type Hb A2 Hb F
β+- Thalasemia increased N to slightly increased
β0- Thalasemia increased N to slightly increased
δβ - Thalasemia Normal Increased (2% - 10%)
HPFH Normal Increased (10% - 40%)
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 21/57
Homozygos states o) -ThalasemiaTye !nemia δ - glo"in
chain
β- glo"in
chain
β- glo"in
m#N!
β- glo"in
$enes
β-Thalasemia e&ere Present 'ecreased 'ecreased Present
β0-Thalasemia e&ere Present !"sent !"sent ora"normal
Present
δβ-Thalasemia ild !"sent !"sent !"sent 'eleted
HPFH None !"sent !"sent !"sent 'eleted
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 22/57
-Thalasemia* Homozygos orms (!a"or an%
interme%ia
athogeneses =ariable reduction of β> chain syntheses *β;, β?, and
variant+
α>chain excess result in intracellular precipitation of in
soluble α> chain $ncreased but ineffective erythropoesis ith many red
cell precursors destroyed is related to α > chain
excess
!hortened red cell life span and variable splenicse1uestration
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 23/57
-Thalasemia* Homozygos orms (!a"or an%
interme%ia
S,.,A, )yperplastic marro: bone marro expansion ith cortical thinning
$ncreased iron absorption and iron overload *caused of repeated
blood transfusion+ #irrhosis of the liver
9ndocrine disturbances e.g diabetes mellitus !in hyperpigmentation
#ardiac hemosiderosis
)ypersplenism lasma voleme expansion
!hortened red cell life
@euopenia
thrombocytopenia
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 24/57
-Thalasemia* Homozygos orms (!a"or an%
interme%ia
H,!AT''01 "nemia: hypochromic, microcytic, lo M#=
3eticulocytosis
@euopenia and thrombocytopenia *may develop+
lood film : target cells and nucleated red cell, anisocytosis,
polychromasia, basophilia, circulating normoblast
3ed cell life span reduced
)b5 raised, )b"2 normal
one marro may be megaloblastic*due to folate depletion+,
erythroid hyperplasia Asmotic fragility decreased
!erum ferritin raised
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 25/57
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 26/57
-Thalasemia* Homozygos orms (!a"or an%
interme%ia
C$3$CA ,AT.2,S 5ailure to thrive "nemia Baundice )epatosplenomegaly
"bnormal facies*prominence of malar eminances, frontal bossing, depression of bridge of nose,
exposure of upper central teeth+ !ull radiographs hair on end appearance 5racture *caused of marro expansion+ osteoporosis
Groth retardation * primary amenorrhea, delayed puberty+ @eg ulcer $f untreated, 7;C die in the first year of life
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 27/57
Clinical )eatres (
thalasemia !evere form of β thalasemia *)omozygous or#ompound heterozygous+ present ithin thefirst year of life
5ailure to thrive Mongoloid face oor feeding 5re1uent infection
General malaise ale !plenomegaly 5re1uent transfusion hemosiderosis
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 28/57
Complicationas a reslt o) these sitation
$nade1uate treatment in the first years of life
oor compliance
9xcessive blood consumption $nsufficient application of chelating agent
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 29/57
Complication
9ndocrine disturbances *retarded groth, delayed puberty,
diabetes, hypogonadism, adrenal insufficiency, hypothyroidism,
hypoparathyroidism+
@iver cirrhosis#ardiac failure
!pinal compression caused by epidural extramedullary
hematopoesis
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 30/57
Cases o) %eath
)epatic and cardiac failure
$ncreased susceptibility to infection post
splenectomy
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 31/57
!anagement
)ypertransfusion to maintain pretransfusion )b%;.D / %% gdl Groth and development are maximized
9xtramedullary hemapoesis is minimized
decreasingfacial and seletal abnormalities Number of α > chain precipitate are reduced prevent
development of splenomegaly and hypersplenism
#helation therapy iron chelating agent
*desferioxamine+ !plenectomy !upportive care
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 32/57
Clinical management
3egular 3ed cell transfusions < ' gdl at monthly interval @o transfusion , not exceeding 6.D gdl
)igh trnsfusion, exceeded %% gdl
$ron overload iron chelating therapy ithdeferoxamine
!plenectomyone marro transplantation
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 33/57
Splenectomy
3educes transfusion re1uirements in
hypersplenism
rophylactic pneumococcal and hemophilus
influenza vaccine and prophylactic life>longpenicilline are needed.
$ndication :
ersistent increase of blood transfusion re1uirement 9vidence of severe leuopenia and thrombocytopenia
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 34/57
Spporti4e care
5olic acid is not necessary in hypertransfusionE %mg daily is needed in untranfused*intermediapatients+
)epatitis vaccination 8igitalis and diuretics in congestive heart failure 9ndocrine intervention : thyroxine,
estrogen,testoteron #holescystectomy Genetic counseling and antenatal diagnosis
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 35/57
0ene therapy
$nsertion of normal globin gene into marro
stem cells
The techni1ue is not fesiable in the near
future
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 36/57
-Thalasemia $nterme%ia
C$3$CA ,AT.2,S
$ncidence : 2 / %;C !yndrome is clinically milder than thalasemia
mayor
Generally do not re1uire transfusion andmaintain )b 0 / %; gdl
)epatosplenomegaly, groth retardation,hyperbilirubinemia, iron over load
arvovirus %6 infection induces transienterythroblatopenia*aplastic crisis+
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 37/57
-Thalasemia $nterme%ia
!anagement
5olic acid % mg daily orally
8iet : avoid eating food hich is rich in iron
#helating therapy, hen serum ferritin hasrisen F2,;;; ngml
Tranfusion are not re1uiredE except aplastic
crises, acute infection
!plenectomy may be re1uired
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 38/57
-Thalasemia !inor or Trait (Heterozygos 5 or+
C$3$CA ,AT.2,S
"symptomatic 8iscovered on routine blood test: slightly reduced hemoglobin,
basophilic stippling, lo M#=, normal 38
8iscovered in family investigation or family history
Mild anemia
hysical examination normal
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 39/57
-Thalasemia !inor or Trait (Heterozygos 5 or+
D$A03'S$S
)b normal or slightly decreased
)ypochromic, microcytic cells, target cells, anisocytosis,
basophilic stippling, lo M#=, normal 3T8
)emoglobin "2 increased F&C, )b 5 midly elevated inD;C cases
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 40/57
re4ention
remarital counselling
8iagnostic renatal "mniocentesis
=illous sampling
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 41/57
Hemoglobinopathies
H )ereditary disorders that can result in
moderate to severe anemia
H asic defect is production of an abnormal
globin chain
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 42/57
Hemoglobinopathy 0enetics
H )omozygous: $nheritance of to genes from
each parent coding for the same type of
abnormal hemoglobin, e.g., )b !!
H )eterozygous: $nheritance of genes from
each parent hich code for a different type of
abnormal hemoglobin each, e.g., )b !#
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 43/57
T i l
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 44/57
Terminology
Hemoglobinopathy
More recently discovered hemoglobins have
been named by the city or location of
discovery:
)b #>)arlem
A i A i% S b tit ti
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 45/57
Amino Aci% Sbstittion
Hemoglobinopathy
Gree letter designates affected globin chain
β
A i A i% S b tit ti
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 46/57
Amino Aci% Sbstittion
Hemoglobinopathy
!uperscript number designates affected amino
acid*s+, e.g.,
β'
A i A i% S b tit ti
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 47/57
Amino Aci% Sbstittion
Hemoglobinopathy
@etters and numbers in parentheses designate the
helical segment and amino acid se1uence in that
segment affected *sometimes omitted+, e.g.,
β'*"(+
A i A i% S b tit ti
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 48/57
Amino Aci% Sbstittion
Hemoglobinopathy
"mino acid substitutions are denoted by the
three letter abbreviation for the normally
occurring amino acid folloed by an arro
folloed by the three letter abbreviation forthe substituted amino acid:
β'*"(+Glu → =al
Cl i)i ti
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 49/57
Classi)ication6
Hemoglobinopathy
H 5unctional "bnormalityH "ggregation
H olymerization
H #rystallization
H Instable hemoglobins
H Methemoglobin
H Axygen affinity
C % T t t
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 50/57
Corse an% Treatment
Sic7le Cell Disease
H !icle cell diseaseH "symptomatic at birth
H !ymptoms appear as percentage of fetal
hemoglobin decreases during first year of life
H Intreated crises increase morbidity and early
death
Co rse an% Treatment
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 51/57
Corse an% Treatment
Sic7le Cell Disease
H @ife span can be significantly increased ith early
and effective treatment
H !tudies of natural populations reveal that
individuals ith sicle cell disease are capable ofnormal life spans
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 52/57
Corse an% Treatment
$n both thalassemia and hemoglobinopathy
therapy is usually supportive rather than
curative
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 53/57
Corse an% Treatment
H lood transfusion is used toH #ontrol severe anemia
H 3educe the ris of complications of sicle
hemoglobinopathies *cerebrovascular accident,hypersplenism, etc.+
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 54/57
Corse an% Treatment
H #hronic blood transfusionH 3esults in iron overload of ma-or organs resulting
in increased morbidity
H @aboratory monitoring
H Necessitates the use of chelating agents to
remove excess iron
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 55/57
Corse an% Treatment
H 9xcess iron can cause the appearance of
sideroblastic conditions
H Transfusion interferes ith the typical laboratory
findings for the disorder
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 56/57
Corse an% Treatment
H "lternative treatmentH "ctivation of fetal hemoglobin genes
H one marro transplantation
7/25/2019 Thalasemia and Hemoglobinopathi
http://slidepdf.com/reader/full/thalasemia-and-hemoglobinopathi 57/57